Neurology and the skin

Journal of Neurology Neurosurgery and Psychiatry

Volumn 66, Issue 4, 1999, Pages 417-430

  Hurko, Orest ^a   Provost, Thomas T ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; COLCHICINE; IMMUNOSUPPRESSIVE AGENT; STEROID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMYLOIDOSIS; ANTIPHOSPHOLIPID SYNDROME; BATTERED CHILD SYNDROME; BEHCET DISEASE; CAFE AU LAIT SPOT; DERMATOMYOSITIS; DIABETIC NEUROPATHY; ECCHYMOSIS; FABRY DISEASE; HERPES ZOSTER; HUMAN; LEPROSY; LYME DISEASE; MELANOMA; MENINGITIS; MENINGOENCEPHALITIS; NEUROFIBROMATOSIS; NEUROLOGIC DISEASE; NEUROPATHY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PURPURA; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SCLERODERMA; SKIN DISEASE; STROKE; SYPHILIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA; XERODERMA PIGMENTOSUM;

EID: 0032969624     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.66.4.417     Document Type: Review

References (115)

1. Fitzpatrick TB, Eisen AZ, Wolff K, et al. eds. Dermatology in general medicine, 3rd ed. New York: McGraw-Hill, 1987.
2. Sontheimer RD, Provost TT, eds. Cutaneous manifestations of rheumatic disease. Baltimore: Williams and Wilkins, 1996.
3. 3Online mendelian inheritance in man (OMIM). http:// www3.ncbi.nlm.nih.gov/Omim.
4. McArthur JC. Neurologic manifestations of AIDS. Medicine 1987;66:407-37.
5. Anderson M. In Neurological emergencies. Hughes RAC, ed. London: BMJ Publishing Group, 1997:225-271.
6. Hudson N, Busque L, Rauch J, et al. Familial antiphospholipid syndrome and HLA-DRB gene associations. Arthritis Rheum 1997;40:1907-8.
7. Moore PM, Richardson B. Neurology of the vasculitides and connective tissue diseases. J Neurol Neurosurg Psychiatry 1998;65:10-22.
8. Khamashta MA, et al. The management of thromboses in the antiphospholipid syndrome. N Engl J Med 1995;332: 993-7.
9. Hasholt L, Sorensen SA, Wandall A, et al. A Fabry's disease heterozygote with a new mutation: biochemical, ultrastructural, and clinical investigations. J Med Genet 1990;27:303-6.
10. Franceschetti AT, Philippart M,. Franceschetti A. A study of Fabry's disease. I. Clinical examination of a family with cornea verticillata. Dermatologica 1969;138:209-21
11. Mutoh T, Senda Y, Sugimura K, et al. Severe orthostatic hypotension in a female carrier of Fabry's disease. Arch Neurol 1988;45:468-72.
12. Broadbent JC, Edwards WD, Gordon H, et al. Fabry cardiomyopathy in the female confirmed by endomyocardial biopsy. Mayo Clin Proc 1981;56:623-8.
13. Bird TD, Lagunoff D. Neurological manifestations of Fabry disease in female carriers. Ann Neurol 1978;4:537-40.
14. Feitosa MF, Borecki I, Krieger H, et al. The genetic epidemiology of leprosy in a Brazilian population. Am J Hum Genet 1995;56:1179-85.
15. Noordeen SK, Bravo L, Sundaresan TK. Estimated number of leprosy cases in the world. Indian J Lepr 1992;64:521-7.
16. Richardus JH, Finlay KM, Croft RP, et al. Nerve function impairment at diagnosis and at completion of MDT: a retrospective cohort study of 786 patients in Bangladesh. Lepr Rev 1996;67:297-305.
17. Van Brakel WH, Khawas IB. Silent neuropathy in leprosy: an epidemiological description. Lepr Rev 1994;65:350-60.
18. Nilsen R, Mengistu G, Reddy BB. The role of nerve biopsies in the diagnosis and management of leprosy. Lepr Rev 1989;60:28-32.
19. Logigian EL. Peripheral nervous system Lyme borreliosis. Semin Neurol 1997;17:25-30.
20. Halperin JJ. Nervous system Lyme disease. J Neurol Sci 1988;153:182-91.
21. Reid MC, Schoen RT, Evans J, et al. The consequences of over diagnosis and over treatment of Lyme disease: an observational study. Ann Intern Med 1998;128:354-62.
22. Sigal LH. Pitfalls in the diagnosis and management of Lyme disease. Arthritis Rheum 1998;41:195-204.
23. Mizuki N, Ota M, Kimura M, et al. Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behçet disease. Proc Natl Acad Sci USA 1997;94:1298-303.
24. Gurler A, Boyvat A, Tursen U. Clinical manifestations of Behçet's disease: an analysis of 2147 patients. Yonsei Med J 1997;38:423-27.
25. Farah S, Al-Shubaili A, Montaser A, et al. Behçet's syndrome: a report of 41 patients with emphasis on neurological manifestations. J Neurol Neurosurg Psychiatry 1998; 64:382-4.
26. Sharma OP, Sharma AM. Sarcoidosis of the nervous system. A clinical approach. Arch Intern Med 1991;151: 1317-21.
27. Stern BJ, Krumholz A, Johns C, et al. Sarcoidosis and its neurological manifestations. Arch Neurol 1985;42:909-17.
28. EW Hook, Marra CM. Acquired syphilis in adults. N Engl J Med 1992;326:1060-9.
29. Rhodes AR, Luger AFH. Syphilis and other treponematoses. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al, eds. Dermatology in general medicine. 3rd ed. New York: McGraw-Hill 1987:2395-451.
30. Mosher DB, Fitzpatrick TB, Ortonee J-P, et al. Disorders of pigmentation. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al, eds. Dermatology in general medicine, 3rd ed. New York: McGraw-Hill, 1987:834-5.
31. Whitley RJ. Varicella virus infections. In: Isselbacher KJ, Braunwald E, Wilson JD, et al, eds. Harrison's principles of internal medicine. 13th ed. New York: McGraw-Hill, 1994: 787-90.
32. Luxon LM. Disorders of hearing. In: Asbury AK, McKhann GM, McDonald WI. Diseases of the nervous system: clinical neurobiology. Philadelphia: WB Saunders, 1992:434-50.
33. Gerber O, Roque C, Coyle PK. Vasculitis owing to infection. Neurol Clin 1997;25:903-25.
34. Billmire ME, Myers PA. Serious head injury in infants: accident or abuse. Pediatrics 1985;75:340-2.
35. Lancon JA, Haines DE, Parent AE. Anatomy of the shaken baby syndrome. Anat Rec 1998;23:13-18.
36. Krugman RD, Bays JA, Chadwick DL, et al. Shaken baby syndrome: inflicted cerebral trauma. Pediatrics 1992;92: 872-5.
37. Ablin DS, Sane SM. Non-accidental injury: confusion with temporary brittle bone disease and mild osteogenesis imperfecta. Pediatr Radiol 1997;27:111-3.
38. Kleinman PK. Diagnostic imaging in infant abuse. AJR Am J Roentgenol 1990;155:703-12.
39. Guzzini F, Conti A, Esposito F. Simultaneous ischemic and hemorrhagic lesions of the brain detected by CT scan in a patient with thrombotic thrombocytopenic purpura Haematologica 1998;83:280.
40. Rund D, Schaap T, Gillis S. Intensive plasmapheresis for severe thrombotic thrombocytopenic purpura: long-term clinical outcome. J Clin Apheresis 1997;12:194-5.
41. M Upadhyaya, DN Cooper. Neurofibromatosis type 1: from genotype to phenotype. Oxford: BIOS, 1998
42. National Institutes of Health Consensus Conference. Neurofibromatosis: conference statement. Arch Neurol 1988:575-8
43. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997;278: 51-72.
44. Ferner RE. Clinical aspects of neurofibromatosis 1. in M. Upadhyaya and DN Cooper, eds. Neurofibromatosis type 1: from genotype to phenotype. Oxford: BIOS, 1998:21-38
45. Matsui I, Tanimura M, Kobayashi N, et al. Neurofibromatosis and childhood cancer. Cancer 1993;72:2746-54.
46. Ferner RE, Hughes RA, Weinman J. Intellectual impairment in neurofibromatosis 1. Neurol Sci 1996;138:125-33.
47. DiMario FJ Jr, Ramsby G. Magnetic resonance imaging lesion analysis in neurofibromatosis type 1. Arch Neurol 1998;55:500-5.
48. Denckla MB, Hofman K, Mazzocco MM et al. Relationship between T2-weighted hyperintensities (unidentified bright objects) and lower IQs in children with neurofibromatosis-1. Am J Med Genet 1996;67:98-102.
49. Ferner RE, Chaudhuri, Bingham J, et al. NRI in neurofibromatosis 1. The nature and evolution of increased intensity T2 weighted lesions and their relationship to intellectual impairment. J Neurol Neurosurg Psychiatry 1993;56:492-5.
50. Vogel KS, Brannan CI, Jenkins NA, et al. Loss of neurofibromin results in neurotrophin-independent survival of embryonic sensory and sympathetic nerurons. Cell 1995;82:733-12.
51. Huson SM, Compston DA, Clark P, et al. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet 1989;26:704-11.
52. Park VM, Pivnick EK. Neurofibromatosis type 1 (NF1): a protein truncation assay yielding identification of mutations in 73% of patients. J Med Genet 1998,35:813-20.
53. Upadhyaya M, Shen M, Cherryson A, et al. Analysis of mutations at the neurofibromatosis l (NF1) locus. Hum Molec Genet 1992;1:735-10.
54. Mautner VF, Lindenau M, Baser ME, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996;38:880-5.
55. Parry DM, Eldridge R, Kaiser-Kupfer MI, et al. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994;52:450-61
56. Pollack IF, Mulvihill JJ. Neurofibromatosis 1 and 2. Brain Pathol 1997;7:823-36.
57. Evans DGR, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603-18.
58. Niimura, M. Neurofibromatosis. Rinsho Derma (Tokyo) 1973;15:653-63.
59. Honda M, Arai E, Sawada S, et al. Neurofibromatosis 2 and neurilemmomatosis gene are identical. J Invest Derm 1995; 104:74-7.
60. Jacoby LB, Jones D, Davis K, et al. Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet 1997;61:1293-02.
61. Evans DG, Mason S, Huson SM, et al. Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study. J Neurol Neurosurg Psychiatry 1997;62:361-6.
62. Seppala MT, Sainio MA, Haltia MJ. Multiple schwannomas: schwannomatosis or neurofibromatosis type 2? J Neurosurg 1998;89:36-41.
63. Webb DW, Clarke A, Fryer A, et al. The cutaneous features of tuberous sclerosis: a population study. Br J Dermatol 1996;35:1-5.
64. Gomez MR. Tuberous sclerosis. New York: Raven Press, 1979.
65. Jones AC, Daniells CE, Snell RG, et al. Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis. Hum Molec Genet 1997;6:2155-61.
66. Smith D. Recognizable patterns of human malformation. 3rd ed. New York: WB Saunders, 1982:148.
67. Weemaes CMR, Hustinx TWJ, Scheres, et al. A new chromosomal instability disorder: the Nijmegen breakage syndrome. Acta Paediat Scand 1981;70:557-64.
68. Smith D. (cited in) Recognizable patterns of human malformation. 3rd ed. New York: WB Saunders, 1982:88.
69. Hagerman DA, Williams G P. Some features of Fanconi's anemia. N Engl J Med 1993;329:1168.
70. Tisherman SE, Gregg FJ, Danowski TS. Familial pheochromocytoma. JAMA 1962;182:152-6.
71. Tisherman SE, Tisherman BG, Tisherman SA, et al. Three-decade investigation of familial pheochromocytoma: an allele of von Hippel-Lindau disease? Arch Intern Med 1993; 153:2550-6.
72. Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995;332:839-47.
73. Endo M, Yamada Y, Matsuura N, et al. Monozygotic twins discordant for the major signs of McCune-Albright syndrome. Am J Med Genet 1991;41:216-20.
74. Hurko O, Uematsu S. Neurosurgical considerations in skeletal dysplasias. Neurosurgical Quarterly 1993;3:192-217.
75. Westerhof W, Beemer FA, Cormane RH et al. Hereditary congenital hypopigmented and hyperpigmented macules. Arch Dermatol 1978;114:931-6.
76. Patton MA. Russell-Silver syndrome. J Med Genet 1998;25: 557-60.
77. Abeliovich D, Gelman-Kohan Z, Silverstein S, et al. Familial cafe au lait spots: a variant of neurofibromatosis type 1. J Med Genet 1995;32:985-6.
78. Charrow J, Listernick R, Ward K. Autosomal dominant multiple cafe-au-lait spots and neurofibromatosis-1: evidence of non-linkage. Am J Med Genet 1993;45:606-8.
79. Pepys MB. Amyloid, familial Mediterranean fever, and acute phase response. In: Weatherall DJ, Ledingham JGG, Worrell DA, eds. Oxford textbook of medicine 3rd ed. Vol 2. Oxford: Oxford University Press, 1996:1512-33.
80. Ducla-Soares J, Alves MM, Carvalho M, et al. Correlation between clinical, electromyographic and dysautonomic evolution of familial amyloidotic polyneuropathy of the Portuguese type. Acta Neurol Scand 1994;90:266-9.
81. Uitti RJ, Donat JR, Rozdilsky B, et al. Familial oculoleptomeningeal amyloidosis: report of a new family with unusual features. Arch Neurol 1988;45:1118-22.
82. Sack GH Jr, Dumars KW, Gummerson KS, et al. Three forms of dominant amyloid neuropathy. Johns Hopkins Med J 1981;149:239-47.
83. Schwabe AD, Monroe JB. Meningitis in familial Mediterranean fever. Am J Med 1988;85:715-7.
84. French FMF consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997;17:25-31.
85. Casey AT, Crockard HA, Geddes JF, et al. Vertical translocation: the enigma of the disappearing atlantodens interval in patients with myelopathy and rheumatoid arthritis. Part I. Clinical, radiological, and neuropathological features. J Neurosurg 1997;87:856-62.
86. Said G. Necrotizing peripheral nerve vasculitis. Neurol Clin 1997;15:835-48.
87. Ramos M, Mandybur TI. Cerebral vasculitis in rheumatoid arthritis. Arch Neurol 1975;32:271-1.
88. Hietaharju A, Jantti V, Korpela M, et al. Nervous system involvement in systemic lupus erythematosus, Sjögren's syndrome, and scleroderma. Acta Neurol Scand 1993;88: 299-308.
89. Adebajo AO, Crisp AJ, Nicholls A, et al. Localised scleroderma and hemiatrophy in association with antibodies to double-stranded DNA. Postgrad Med J 1992;68:216-8.
90. Yasuda T, Kumazawa K, Sobue G. Sensory ataxic neuropathy associated with Sjögren's syndrome. Nippon Rinsho 1995;53:2568-73.
91. Alexander EL, Provost TT, Stevens MB, et al. Neurologic complications of primary Sjögren's syndrome. Medicine 1982;61:247-57.
92. Alexander E. Central nervous system disease in Sjögren's syndrome: new insights in immunopathogenesis. Rheum Dis Clin North Am 1992;18:637-62.
93. Molina R, Provost TT, Alexander EL. Peripheral inflammatory vascular disease in Sjögren's syndrome: associations with nervous system complications. Arthritis Rheum 1985; 28:1341-7.
94. Guillevin L, Lhote FR. Gherardi polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: clinical aspects, neurologic manifestations, and treatment. In: Younger DS, ed. Neurologic clinics. Vasculitis and the nervous system 1997;154:865-86.
95. Gutmann DH, Fischbeck KH, Sergott RC. Hereditary retinal vasculopathy with cerebral white matter lesions. Am J Med Genet 1989;34:217-20.
96. Tsao BP, Cantor RM, Kalunian KC, et al. Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J Clin Invest 1997;99:725-31.
97. Dawkins MA, Jorizzo JL, Walker FO, et al. Dermatomyositis: a dermatology-based case series. J Am Acad Dermatol 1998;38:397-404.
98. Mantegazza R, Bernasconi P, Confalonieri P, et al. Inflammatory myopathies and systemic disorders: a review of immunopathogenetic mechanisms and clinical features. J Neurol 1997;244:277-87.
99. Amato AA, Barohn RJ. Idiopathic inflammatory myopathies. Neurol Clin 1997;15:615-18.
100. Targoff IN. Immune manifestations of inflammatory muscle disease. Rheum Dis Clin North Am 1994;20:857-80.
101. Whitmore S, Rosenshein NB, Provost TT. Ovarian cancer in patients with dermatomyositis. Medicine 1994;73:153-60.
102. Desnick R.J. The porphyrias. In: Isselbacher KJ, Braunwald E, Wilson JD, et al, eds. Harrison's principles of internal medicine. 13th ed. New York: McGraw-Hill, 1994;2073-9.
103. Wilson JD. Vitamin deficiency and excess. In: Isselbacher KJ, Braunwald E, Wilson JD, et al, eds. Harrison's principles of internal medicine. 13th ed. New York: McGraw-Hill, 1994;472-80.
104. Levy HL, Madigan PM, Shih VE. Massachusetts metabolic screening program. I. Technique and results of urine screening. Pediatrics 1972;49:825-36.
105. Cheminal R, Echenne B, Bellet H, et al. Congenital non-progressive encephalopathy and deafness with intermittent episodes of coma and hyperkynureninuria. J Inherit Metab Dis 1996;19:25-30.
106. Bootsma D, Hoeijmakers JH. The genetic basis of xeroderma pigmentosum. Ann Gener 1991;34:143-50.
107. Neill, CA, Dingwall MM. A syndrome resembling progeria: a review of two cases. Arch Dis Child 1950;25: 213-223.
108. Schmickel RD, Chu EH, Trosko JE, et al. Cockayne syndrome: a cellular sensitivity to ultraviolet light. Pediatrics 1977 Aug;60:135-139.
109. Happle R, Traupe H, Grobe H, et al.. The Tay syndrome (congenital ichthyosis with trichothiodystrophy). Europ J Pediat 1984;141:147-152
110. Cabana MD, Crawford TO, Winkelstein JA, et al. Consequences of the delayed diagnosis of ataxiatelangiectasia. Pediatrics 1998;102:98-100.
111. AJ Sober, Koh HK. Skin cancer. In: Isselbacher KJ, Braunwald E, Wilson JD, et al, eds. Harrison's principles of internal medicine. 13th ed. New York: McGraw-Hill 1994;1866-7.
112. Goldstein AM, Goldin LR, Dracopoli NC, er al. Two-locus linkage analysis of cutaneous malignant melanoma/ dysplastic nevi. Am J Hum Genet 1996;58:1050-6.
113. Azizi E, Friedman J, Pavlovsky F, et al. Familial cutaneous malignant melanoma and tumors of the nervous system. Cancer 1995;76:1571-8.
114. Kaufman DK, Kimmel DW, Parisi JE, et al. A familial syndrome with cutaneous malignant melanoma and cerebral astrocytoma. Neurology 1993;43:1728-31.
115. Reed WB, Becker SW, Becker SW Jr, et al. Giant pigmented nevi, melanoma, and leptomeningeal melanocytosis: a clinical and histopathological study. Arch Dermatol 1965;91:100-19.